Arcus Biosciences, Inc.
RCUS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001724521
In the last 90 days, Arcus Biosciences, Inc. insiders filed 0 open-market purchases and 2 sales; 231 institutions reported holding it in 13F filings for Q2 2026, worth $3.78B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Arcus Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 2 filings
- 2 insiders, $2.12M in total
- Insiders trading
- 2
- Net value
- −$2.12M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Arcus Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Azoy Alexander | Chief Accounting Officer | 39,581 | Aug 24, 2026 | 6 |
| Jaen Juan C. | President | 822,240Indirect | Jul 13, 2026 | 9 |
| Perlman Andrew J | Director | 48,325 | Jun 12, 2026 | 1 |
| Falberg Kathryn E | Director | 44,300 | Jun 12, 2026 | 1 |
| Kaneko Yasunori | Director | 25,700 | Jun 12, 2026 | 1 |
| Machado Patrick | Director | 44,300 | Jun 12, 2026 | 1 |
| Lacey David L. | Director | 76,652 | Jun 12, 2026 | 1 |
| Lambert Nicole | Director | 43,000 | Jun 12, 2026 | 1 |
| Ribas Antoni | Director | 44,300 | Jun 12, 2026 | 2 |
| Tang Carolyn C. | General Counsel | 184,607 | Jun 12, 2026 | 3 |
| Goeltz II Robert C. | Chief Financial Officer | 84,161 | May 12, 2026 | 6 |
| Rosen Terry J | Chief Executive Officer | 2,236,409 | Jan 26, 2026 | 4 |
| Jarrett Jennifer | Chief Operating Officer | 224,024 | Jan 26, 2026 | 4 |
| Markus Richard | Chief Medical Officer | 89,647 | Jan 26, 2026 | 2 |
| Gilead Sciences, Inc. | 10% Owner | 31,424,760 | Feb 20, 2025 | 0 |
| Nuyten Dimitry SA | Chief Medical Officer | 87,518 | Dec 17, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 26, 2025 (view filing) | Nov 26 | Same day | Goeltz II Robert C.Chief Financial Officer | SSale | −5.00K | $25.00 | −$125.0K | −5.4%87.1K after | 10b5-1 |
| Dec 1, 2025 (view filing) | Nov 26 | 5 days | Azoy AlexanderChief Accounting Officer | SSale | −1.90K | $26.00 | −$49.4K | −6.5%27.4K after | 10b5-1 |
| Dec 5, 2025 (view filing) | Dec 4 | 1 day | Jaen Juan C.President | SSale | −83.0K | $24.71 | −$2.05M | −8.0%954.1K after | 10b5-1 |
| Dec 18, 2025 (view filing) | Dec 16-17 | 2 days | Rosen Terry JChief Executive Officer | SSale | −54.7K | $22.01 | −$1.20M | −2.4%2.19M after | 2 lots10b5-1 |
| Dec 18, 2025 (view filing) | Dec 16-17 | 2 days | Jaen Juan C.President | SSale | −21.2K | $22.01 | −$466.8K | −5.8%346.0K after | 2 lots10b5-1 |
| Dec 18, 2025 (view filing) | Dec 16-17 | 2 days | Goeltz II Robert C.Chief Financial Officer | SSale | −12.7K | $22.01 | −$278.7K | −14.5%74.5K after | 2 lots10b5-1 |
| Dec 18, 2025 (view filing) | Dec 16-17 | 2 days | Jarrett JenniferChief Operating Officer | SSale | −21.2K | $22.01 | −$466.8K | −9.9%193.0K after | 2 lots10b5-1 |
| Dec 18, 2025 (view filing) | Dec 16-18 | 2 days | Azoy AlexanderChief Accounting Officer | SSale | −8.83K | $22.13 | −$195.4K | −32.3%18.5K after | 3 lots10b5-1 |
| Dec 18, 2025 (view filing) | Dec 16-17 | 2 days | Tang Carolyn C.General Counsel | SSale | −14.5K | $22.01 | −$318.5K | −10.4%124.7K after | 2 lots10b5-1 |
| Dec 18, 2025 (view filing) | Dec 16-17 | 2 days | Markus RichardChief Medical Officer | SSale | −9.55K | $22.01 | −$210.1K | −12.7%65.6K after | 2 lots10b5-1 |
| Jan 2, 2026 (view filing) | Dec 31, 2025 | 2 days | Goeltz II Robert C.Chief Financial Officer | SSale | −6.55K | $23.38 | −$153.2K | −8.8%67.9K after | 10b5-1 |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Jaen Juan C.President | SSale | −31.8K | $21.41 | −$681.3K | −3.3%922.2K after | 3 lots10b5-1 |
| May 12, 2026 (view filing) | May 11 | 1 day | Goeltz II Robert C.Chief Financial Officer | SSale | −7.76K | $25.63 | −$199.0K | −8.4%84.2K after | 10b5-1 |
| Jun 1, 2026 (view filing) | Jun 1 | Same day | Azoy AlexanderChief Accounting Officer | SSale | −2.56K | $25.77 | −$66.0K | −6.1%39.6K after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22-24 | 2 days | Jaen Juan C.President | SSale | −31.4K | $27.92 | −$877.5K | −3.4%890.8K after | 4 lots10b5-1 |
| Jul 13, 2026 (view filing)5:36 PM ET | Jul 9-10 | 4 days | Jaen Juan C.President | SSale | −68.6K | $29.63 | −$2.03M | −7.7%822.2K after | 3 lots10b5-1 |
| Aug 24, 2026 (view filing)5:52 PM ET | Aug 21 | 3 days | Azoy AlexanderChief Accounting Officer | SSale | −2.83K | $30.00 | −$84.8K | −6.7%39.6K after | 10b5-1 |